trending Market Intelligence /marketintelligence/en/news-insights/trending/3hmal2os5egcusdker0e8q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Intellipharmaceutics closes $1.8M direct offering of common stock

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Intellipharmaceutics closes $1.8M direct offering of common stock

Intellipharmaceutics International Inc. closed its registered direct offering of 3 million common shares priced at 60 cents apiece with gross proceeds of about $1.8 million.

The company also issued to the investors unregistered warrants to buy 1.5 million shares at an exercise price of 60 cents apiece.

Intellipharmaceutics raised about $1.5 million in net proceeds through this offering.

The company plans to use the net proceeds for general corporate purposes, which may include working capital, capital expenditures, research and development, accounts payable and other commercial expenditures.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Intellipharmaceutics recently raised $3.5 million through a separate offering that closed March 16.

Toronto-based Intellipharmaceutics International is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid dosage drugs.